EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial

Xiaosong Chen iD, Jiahui Huang, Haoting Shi iD, Juanying Zhu, Weizhu Wu, Guolin Ye, Qi He, Yong Shi, Anqin Zhang, Xiaohong Xie iD, Xiaodong Wang, Xiangjing Chen und 13 weitere

Journal of Clinical Oncology · 20.01.2026 · 44 (3) · 143-152

DOI: 10.1200/jco-25-02412 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2026. Verfasst von Xiaosong Chen und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Carboplatin, Antineoplastic Combined Chemotherapy Protocols, Taxoids. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate the efficacy and safety of adjuvant epirubicin plus cyclophosphamide followed by taxanes (EC-T) versus EC-T plus carboplatin (EC-TCb) in patients with early-stage triple-negative breast cancer (TNBC). PATIENTS AND METHODS In this phase III trial, patients with TNBC with node-positive or node-negative (tumor size ≥1.0 cm) disease who received definitive surgery, were stratified by lymph node status and randomly assigned in a 1:1 ratio to receive four cycles of EC followed by four cycles T with or without carboplatin adjuvant chemotherapy. The primary end point was disease-free survival (DFS). Secondary end points included distant DFS (DDFS), overall survival (OS), and safety. This study had 80% power to detect a DFS hazard ratio (HR) of 0.64, with a two-sided type I error of 0.05. RESULTS A total of 786 patients were randomly assigned to receive EC-T (n = 391) or EC-TCb (n = 395) between March 2016 and March 2023. With a median follow-up of 4.52 (IQR, 2.83-6.06) years, 62 and 41 events were reported in the EC-T and EC-TCb arm, respectively. Adding carboplatin significantly improved DFS (HR, 0.66; [95% CI, 0.44 to 0.97]; P = .034), DDFS (HR, 0.61 [95% CI, 0.38 to 0.98]; P = .040), and OS (HR, 0.39 [95% CI, 0.16 to 0.94]; P = .029). Grade 3 to 4 adverse events were more frequent among the EC-TCb arm (49.9%) than the EC-T arm (38.7%), primarily driven by higher incidence of neutropenia (47.0% v 37.8%) and thrombocytopenia (4.5% v 0%). Other grade 3 to 4 toxicities were comparable. CONCLUSION Adding carboplatin to adjuvant EC-T chemotherapy significantly improves DFS, DDFS, and OS in patients with early-stage TNBC. Although increased hematologic toxicity was observed, no new safety signals emerged.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCarboplatinAntineoplastic Combined Chemotherapy ProtocolsTaxoidsHumansFemaleCyclophosphamideEpirubicinMiddle AgedChemotherapy, AdjuvantAdultAgedNeoplasm StagingDisease-Free Survival

Substanzen

CarboplatinCyclophosphamideEpirubicinTaxoids

Autor:innen und Institutionen

  • Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Breast, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, Zhejiang, China.
  • Department of Thyroid and Breast Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China.
  • Department of Breast, The First People's Hospital of Foshan, Foshan, Guangdong, China.
  • Department of Breast, The International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Thyroid and Breast Surgery, Lishui People's Hospital, Lishui, Zhejiang, China.

ORCID-Profile: Xiaosong Chen, Haoting Shi, Xiaohong Xie, Mark Daniel Pegram, Kunwei Shen

Zitieren

APA

Chen, X., Huang, J., Shi, H., Zhu, J., Wu, W., Ye, G., He, Q., Shi, Y., Zhang, A., Xie, X., Wang, X., Chen, X., Wu, W., Wu, J., Li, Z., Li, Z., Dai, Y., Ren, W., Shao, Q., …, & Shen, K. (2026). Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. Journal of Clinical Oncology, 44(3), 143-152. https://doi.org/10.1200/jco-25-02412

Vancouver

Chen X, Huang J, Shi H, Zhu J, Wu W, Ye G, et al. Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. Journal of Clinical Oncology. 2026;44(3):143-152. doi:10.1200/jco-25-02412

BibTeX
@article{Chen2026,
  author = {Chen, Xiaosong and Huang, Jiahui and Shi, Haoting and Zhu, Juanying and Wu, Weizhu and Ye, Guolin and He, Qi and Shi, Yong and Zhang, Anqin and Xie, Xiaohong and Wang, Xiaodong and Chen, Xiangjing and Wu, Weili and Wu, Jundong and Li, Zhian and Li, Zhanwen and Dai, Yuechu and Ren, Weili and Shao, Qing and Chen, Yongan and Zeng, Yong and Zhang, Fengzhe and Dong, Shuwen and Pegram, Mark Daniel and Shen, Kunwei},
  title = {Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {3},
  pages = {143--152},
  doi = {10.1200/jco-25-02412}
}
Kostenlos starten →